NATCO Pharma Limited (NSE:NATCOPHARM)
India
· Delayed Price · Currency is INR 830.30
+5.20 (0.63%)
May 14, 2025, 1:11 PM IST
NATCO Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Operating Revenue | 39,988 | 27,071 | 19,448 | 20,521 | 19,150 | Upgrade
|
| Other Revenue | 32 | 14 | 14 | 40 | - | Upgrade
|
| Revenue | 40,020 | 27,085 | 19,462 | 20,561 | 19,150 | Upgrade
|
| Revenue Growth (YoY) | 47.76% | 39.17% | -5.34% | 7.37% | -8.57% | Upgrade
|
| Cost of Revenue | 7,487 | 6,544 | 5,845 | 5,318 | 4,060 | Upgrade
|
| Gross Profit | 32,533 | 20,541 | 13,617 | 15,243 | 15,090 | Upgrade
|
| Selling, General & Admin | 5,309 | 4,625 | 4,806 | 4,390 | 4,719 | Upgrade
|
| Other Operating Expenses | 9,599 | 6,072 | 5,952 | 4,634 | 4,461 | Upgrade
|
| Operating Expenses | 16,827 | 12,443 | 12,383 | 10,310 | 10,233 | Upgrade
|
| Operating Income | 15,706 | 8,098 | 1,234 | 4,933 | 4,857 | Upgrade
|
| Interest Expense | -203 | -148 | -132 | -93 | -177 | Upgrade
|
| Interest & Investment Income | 1,013 | 513 | 392 | 566 | 791 | Upgrade
|
| Currency Exchange Gain (Loss) | 103 | 214 | 103 | 40 | 51 | Upgrade
|
| Other Non Operating Income (Expenses) | 97 | 130 | -3 | 30 | 2 | Upgrade
|
| EBT Excluding Unusual Items | 16,716 | 8,807 | 1,594 | 5,476 | 5,524 | Upgrade
|
| Merger & Restructuring Charges | - | -291 | -11 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -7 | -52 | 12 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -17 | 178 | 427 | 320 | 163 | Upgrade
|
| Asset Writedown | - | -23 | - | - | - | Upgrade
|
| Pretax Income | 16,735 | 8,619 | 2,022 | 5,796 | 5,687 | Upgrade
|
| Income Tax Expense | 2,852 | 1,466 | 322 | 1,372 | 1,106 | Upgrade
|
| Earnings From Continuing Operations | 13,883 | 7,153 | 1,700 | 4,424 | 4,581 | Upgrade
|
| Net Income to Company | 13,883 | 7,153 | 1,700 | 4,424 | 4,581 | Upgrade
|
| Minority Interest in Earnings | - | - | - | -15 | 27 | Upgrade
|
| Net Income | 13,883 | 7,153 | 1,700 | 4,409 | 4,608 | Upgrade
|
| Net Income to Common | 13,883 | 7,153 | 1,700 | 4,409 | 4,608 | Upgrade
|
| Net Income Growth | 94.09% | 320.76% | -61.44% | -4.32% | -28.49% | Upgrade
|
| Shares Outstanding (Basic) | 179 | 183 | 182 | 182 | 182 | Upgrade
|
| Shares Outstanding (Diluted) | 179 | 183 | 182 | 182 | 182 | Upgrade
|
| Shares Change (YoY) | -1.67% | 0.08% | -0.04% | 0.02% | -1.26% | Upgrade
|
| EPS (Basic) | 77.34 | 39.18 | 9.32 | 24.20 | 25.33 | Upgrade
|
| EPS (Diluted) | 77.34 | 39.18 | 9.32 | 24.16 | 25.26 | Upgrade
|
| EPS Growth | 97.40% | 320.39% | -61.42% | -4.35% | -27.56% | Upgrade
|
| Free Cash Flow | 8,722 | 7,028 | -1,863 | 442 | 616 | Upgrade
|
| Free Cash Flow Per Share | 48.59 | 38.50 | -10.21 | 2.42 | 3.38 | Upgrade
|
| Dividend Per Share | 9.500 | 5.500 | 4.500 | 5.250 | 6.750 | Upgrade
|
| Dividend Growth | 72.73% | 22.22% | -14.29% | -22.22% | 8.00% | Upgrade
|
| Gross Margin | 81.29% | 75.84% | 69.97% | 74.13% | 78.80% | Upgrade
|
| Operating Margin | 39.25% | 29.90% | 6.34% | 23.99% | 25.36% | Upgrade
|
| Profit Margin | 34.69% | 26.41% | 8.73% | 21.44% | 24.06% | Upgrade
|
| Free Cash Flow Margin | 21.79% | 25.95% | -9.57% | 2.15% | 3.22% | Upgrade
|
| EBITDA | 17,506 | 9,669 | 2,600 | 6,066 | 5,822 | Upgrade
|
| EBITDA Margin | 43.74% | 35.70% | 13.36% | 29.50% | 30.40% | Upgrade
|
| D&A For EBITDA | 1,800 | 1,571 | 1,366 | 1,133 | 965 | Upgrade
|
| EBIT | 15,706 | 8,098 | 1,234 | 4,933 | 4,857 | Upgrade
|
| EBIT Margin | 39.25% | 29.90% | 6.34% | 23.99% | 25.36% | Upgrade
|
| Effective Tax Rate | 17.04% | 17.01% | 15.93% | 23.67% | 19.45% | Upgrade
|
| Revenue as Reported | 41,269 | 28,117 | 20,438 | 21,557 | 20,224 | Upgrade
|
| Advertising Expenses | - | - | 326 | 211 | 936 | Upgrade
|
Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.